Disc Medicine Inc
For the period ended Dec 31, 2023. Filed Mar 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 21, 2024
IRON$84.64+4.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(In thousands)
| Year EndedDecember 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash flows from operating activities | ||
| Net loss | $(76,429) | $(46,827) |
| Adjustments to reconcile net loss to net cash used in operations: | ||
| Depreciation and amortization | 100 | 89 |
| Stock-based compensation | 5,530 | 2,089 |
| Change in fair value of derivative liability | — | 61 |
| Noncash lease expense | 290 | 211 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (1,166) | 352 |
| Other assets | — | 64 |
| Accounts payable | (3,741) | 526 |
| Accrued expenses | 2,008 | 1,502 |
| Operating lease liabilities | (54) | (319) |
| Net cash used in operating activities | (73,462) | (42,252) |
| Cash flow from investing activities | ||
| Purchases of property and equipment | (89) | (151) |
| Net cash used in investing activities | (89) | (151) |
| Cash flow from financing activities | ||
| Proceeds from sale of common stock in offerings, net of issuance costs paid | 199,078 | — |
| Proceeds from sale of pre-funded warrants in offerings, net of issuance costs paid | 37,579 | — |
| Proceeds from the issuance of common stock in pre-closing financing | — | 53,500 |
| Cash acquired in connection with the reverse recapitalization | — | 97,403 |
| Payment of reverse recapitalization transaction costs | — | (2,144) |
| Proceeds from stock option exercises | 2,722 | 219 |
| Net cash provided by financing activities | 239,379 | 148,978 |
| Net increase in cash, cash equivalents and restricted cash | 165,828 | 106,575 |
| Cash, cash equivalents and restricted cash, beginning of period | 194,788 | 88,213 |
| Cash, cash equivalents and restricted cash, end of period | $360,616 | $194,788 |
| Supplemental cash flow information | ||
| Cash paid for income taxes | $112 | $— |
| Supplemental disclosure of non-cash activities | ||
| Purchases of property and equipment included in accounts payable and accrued expenses | $13 | $— |
| Right-of-use assets obtained in exchange for new operating lease liabilities | $1,106 | $— |
| Net decrease in right-of-use assets related to lease modifications and reassessment events | $317 | $— |
| Net decrease in operating lease liabilities due to lease modifications and reassessment events | $287 | $— |
| Receivable for proceeds from stock option exercises included in other current assets | $41 | $— |
| Deferred issuance costs on sale of common stock and pre-funded warrants in offerings included in accounts payable and accrued expenses | $225 | $5,792 |
| Settlement of derivative liability upon issuance of common stock to Roche | $— | $6,511 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.